Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Effects of filtration on the presence of particulate and oxycodone content of injections prepared from crushed OxyContin® tablets.

Patel P, Patel RP, Brandon S, McLean S, Bruno R, de Graaff B.

Curr Drug Saf. 2012 Jul;7(3):218-24.

PMID:
22950988
2.

Filtration of crushed tablet suspensions has potential to reduce infection incidence in people who inject drugs.

Ng H, Patel RP, Bruno R, Latham R, Wanandy T, McLean S.

Drug Alcohol Rev. 2015 Jan;34(1):67-73. doi: 10.1111/dar.12196. Epub 2014 Sep 6.

PMID:
25196921
3.

Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets.

McLean S, Bruno R, Brandon S, de Graaff B.

Harm Reduct J. 2009 Dec 22;6:37. doi: 10.1186/1477-7517-6-37.

4.

Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users.

Roux P, Carrieri MP, Keijzer L, Dasgupta N.

Drug Alcohol Rev. 2011 May;30(3):287-90. doi: 10.1111/j.1465-3362.2011.00285.x.

PMID:
21545559
5.

In line final filters for removing particles from amphotericin B infusions.

Huber RC, Riffkin C.

Am J Hosp Pharm. 1975 Feb;32(2):173-6.

PMID:
237416
6.

The role of syringe filters in harm reduction among injection drug users.

Caflisch C, Wang J, Zbinden R.

Am J Public Health. 1999 Aug;89(8):1252-4.

7.

Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.

Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E.

J Opioid Manag. 2012 Sep-Oct;8(5):315-27. doi: 10.5055/jom.2012.0131.

PMID:
23247908
9.

Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB.

Pain Med. 2015 Nov;16(11):2142-51. doi: 10.1111/pme.12834. Epub 2015 Jun 22.

PMID:
26108255
11.

Particles shed from syringe filters and their effects on agitation-induced protein aggregation.

Liu L, Randolph TW, Carpenter JF.

J Pharm Sci. 2012 Aug;101(8):2952-9. doi: 10.1002/jps.23225. Epub 2012 Jun 6.

PMID:
22674153
12.

Contamination control in nursing with filtration. Part 1: filters applied to intravenous fluids and point-of-use hospital water.

Ortolano GA, Russell RL, Angelbeck JA, Schaffer J, Wenz B.

J Infus Nurs. 2004 Mar-Apr;27(2):89-103. Review.

PMID:
15085036
13.

Cigarettes with defective filters marketed for 40 years: what Philip Morris never told smokers.

Pauly JL, Mepani AB, Lesses JD, Cummings KM, Streck RJ.

Tob Control. 2002 Mar;11 Suppl 1:I51-61. Review.

14.

Consequences of microbial contamination during extended intravenous therapy using inline filters.

Rusmin S, Althauser MB, DeLuca PP.

Am J Hosp Pharm. 1975 Apr;32(4):373-7.

PMID:
805533
15.

Glass contamination in parenterally administered medication.

Preston ST, Hegadoren K.

J Adv Nurs. 2004 Nov;48(3):266-70.

PMID:
15488040
16.

Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.

Lofwall MR, Moody DE, Fang WB, Nuzzo PA, Walsh SL.

J Clin Pharmacol. 2012 Apr;52(4):600-6. doi: 10.1177/0091270011401620. Epub 2011 May 24. No abstract available.

17.

[Filtering effectiveness of conventional 15 m micron filters (DIN 58362) and newly developed 15 m micron and 5 m micron filters. I: Particle count].

Walpot H, Franke RP, Burchard WG, Agternkamp C, Müller FG, Mittermayer C, Kalff G.

Infusionstherapie. 1989 Apr;16(2):77-80. German.

PMID:
2737765
18.
19.

Disintegration of chemotherapy tablets for oral administration in patients with swallowing difficulties.

Siden R, Wolf M.

J Oncol Pharm Pract. 2013 Jun;19(2):145-50. doi: 10.1177/1078155212455446. Epub 2012 Aug 20.

PMID:
22907947
20.

Non-medical use of OxyContin Tablets in the United States.

Sees KL, Di Marino ME, Ruediger NK, Sweeney CT, Shiffman S.

J Pain Palliat Care Pharmacother. 2005;19(2):13-23.

PMID:
16061457
Items per page

Supplemental Content

Write to the Help Desk